Ongoing clinical trials

Phase 2 in CKD and suspected MASH

Recruiting

We are aiming to assess the effect of Vonafexor on kidney function in subjects with impaired renal function and suspected MASH.

This clinical study is designed to establish the effect of 2 doses of Vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (eGFR) and suspected metabolic dysfunction-associated steatohepatitis (MASH). Learn more about the clinical study

Phase 2 ALPESTRIA-1 in Alport syndrome

Active, not recruiting

We are aiming to preserve kidney function and reverse kidney damage with the investigational drug Vonafexor tested in our Phase 2 clinical study named “ALPESTRIA-1”: Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome. Learn more about ALPESTRIA-1 clinical study